Clinical development of targeted and immune based anti-cancer therapies

Autor: Angelica M. Merlot, Alexandra E. Stacy, Nicole A. Seebacher, G. M. Porter
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Cancer Research
Small molecule inhibitors
Review
medicine.disease_cause
lcsh:RC254-282
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Immune system
Targeted therapies
Clinical trials
Drug Development
Neoplasms
Biomarkers
Tumor
Medicine
Anaplastic lymphoma kinase
Animals
Humans
Epidermal growth factor receptor
Molecular Targeted Therapy
Clinical Trials as Topic
biology
Cell growth
business.industry
Cancer
medicine.disease
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Combined Modality Therapy
3. Good health
Vascular endothelial growth factor
030104 developmental biology
Treatment Outcome
Oncology
chemistry
030220 oncology & carcinogenesis
Cancer cell
Cancer research
biology.protein
Monoclonal antibodies
Immunotherapy
business
Carcinogenesis
Immunotherapies
Zdroj: Journal of Experimental & Clinical Cancer Research, Vol 38, Iss 1, Pp 1-39 (2019)
Journal of Experimental & Clinical Cancer Research : CR
ISSN: 1756-9966
DOI: 10.1186/s13046-019-1094-2
Popis: Cancer is currently the second leading cause of death globally and is expected to be responsible for approximately 9.6 million deaths in 2018. With an unprecedented understanding of the molecular pathways that drive the development and progression of human cancers, novel targeted therapies have become an exciting new development for anti-cancer medicine. These targeted therapies, also known as biologic therapies, have become a major modality of medical treatment, by acting to block the growth of cancer cells by specifically targeting molecules required for cell growth and tumorigenesis. Due to their specificity, these new therapies are expected to have better efficacy and limited adverse side effects when compared with other treatment options, including hormonal and cytotoxic therapies. In this review, we explore the clinical development, successes and challenges facing targeted anti-cancer therapies, including both small molecule inhibitors and antibody targeted therapies. Herein, we introduce targeted therapies to epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), human epidermal growth factor receptor 2 (HER2), anaplastic lymphoma kinase (ALK), BRAF, and the inhibitors of the T-cell mediated immune response, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein-1 (PD-1)/ PD-1 ligand (PD-1 L).
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje